Summary of the technology
Mutant Human Embryonic Stem Cells
Project ID : 34-2011-2687
Description of the technology
Human embryonic stem cell lines derived from Pre-Implantation Genetic Diagnosis (PGD) embryos
Mutant Human Embryonic Stem Cells , drug screening, genetic disorders
Stem Cell Research Laboratory, Medical Genetics Institute, Shaare Zedek Medical Center
The Stem Cell Research Laboratory is a part of the Medical Genetics Institute in SZMC, which is the largest PGD performing center in the country and one of the leading PGD centers worldwide. The laboratory provides mutant HESC lines. Additionally, the lab investigates basic biological questions related to specific genetic disorders using mutant human embryonic stem cell lines as a model system.
Drug screening- HESCs can potentially differentiate into all cell types in large numbers, so that the targeted tissues will be accessible for large-scale screening
Toxicology assessments of new drug candidates
Development of new therapeutic protocols, including gene therapy-based treatments
Improving the currently available treatments by identifying new drug targets
Invaluable resource to explore unresolved questions related to the biology of particular disorders in human.
Appropriate equipment, for growing human embryos in culture and for the derivation and propagation of human embryonic stem cell lines from 5-7 day old IVF derived human embryos.
A unique access to early stage genetically diseased human embryos
A board collection of genetically inherited diseases with a wide range of naturally inherited mutations.
An unlimited cell source for impaired cells in culture
Favourable over currently available human-based cellular models: do not require establishing cultures from biopsies of patients, unrestricted life span, can differentiate into all cell types
Understanding the pathology of particularly large trinucleotide repeat expansions, namely fragile X syndrome (FRAXA) and Myotonic Dystrophy type 1 (DM1)
The mechanisms by which HESCs regulate telomere length
Potential to derive HESC lines from healthy surplus IVF embryos (IRB 17/11)
Potential to obtain somatic cells from patients for the establishment of disease specific induced pluripotent stem (iPS) cells (initial stages of approval by SZMC's ethic committee).
Rachel Eiges, PhD: Head of the Stem Cell Research Laboratory, Shaare Zedek Medical Center.
, tel: +972-26666721, fax: +972-26666935
VP, Head of Business Development, Healthcare
Shaare Zedek Medical Center,
About Yissum - Research Development Company of the Hebrew University
Technology Transfer Office from IsraelYissum - Research Development Company of the Hebrew University
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.